Introduction {#sec1}
============

Cell therapies to reverse muscle atrophy and to strengthen skeletal muscle would greatly enhance and extend the lives of patients with muscle wasting conditions due to diseases and/or aging. Embryonic stem cells (ESCs) have unlimited proliferation potential, and no need for locating a suitable immunotype-matched donor as with adult-derived stem cells ([@bib5]). However, a major obstacle in the development of ESC-based therapies targeting muscle has been the generation of a homogeneous myogenic population from in vitro differentiation, thus requiring optimization to enrich for muscle lineage cells.

Several studies have validated the potential of mouse and human ESCs (mESCs and hESCs, respectively) and induced pluripotent stem cells (iPSCs), in skeletal muscle therapy ([@bib7; @bib11; @bib17; @bib18; @bib19; @bib20; @bib51]). Cells were differentiated into paraxial mesoderm-like muscle progenitors, either by a standard serum-based embryoid body (EB) differentiation protocol ([@bib11; @bib51]) or by transient expression of PAX3 or PAX7 ([@bib17; @bib18; @bib20]). These in vitro derived progenitors were able to engraft into adult myofibers of mice, replenish the muscle stem cell (satellite cell) niche, and enhance muscle contractile function ([@bib11; @bib17; @bib18; @bib20; @bib51]). Despite promising results, these protocols are not appropriate for the generation of muscle progenitor cells (MPC) for clinical applications due to the inefficiency of differentiation and the use of viral vectors and potential insertional mutations ([@bib56]).

Previous studies from our lab have used a serum-containing EB-induced differentiation supplemented with low levels of retinoic acid (RA) to enhance myogenesis from mouse ([@bib30]) and human ([@bib50]) ESCs. However, serum-containing EB-differentiation of hESCs produced relatively low yields of skeletal muscle (\<5%) and is undefined ([@bib2; @bib30; @bib50]). In contrast, directed differentiation uses knowledge of embryogenesis to recreate embryonic conditions in vitro using combinations of signaling molecules, to support the differentiation into one lineage ([@bib39]). Applying the serum-free directed differentiation approach should greatly improve the efficiency of hESC-derived myogenesis for molecular analysis and for future use in cell therapies.

Wnt signaling is critically important for the development of the primitive streak and paraxial mesoderm ([@bib34]), marked by the T and MSGN1 or TBX6 genes, respectively, and in the formation of posterior somites and the tail bud ([@bib54]), marked by the transcription factors PAX3, MEOX1, and PAX7. In the canonical pathway (reviewed in [@bib15]), Wnt binds to Frizzled cell-surface receptors, initiating a signaling cascade that inhibits GSK3B, preventing B-CATENNIN (CTNNB1) degradation, and allowing CTNNB1 to accumulate and translocate into the nucleus. Nuclear CTNNB1 enhances transcription by interaction with T cell factors or lymphocyte enhancer factors ([@bib15]).

It has previously been shown that the GSK3 inhibitor CHIR99021 (CHIR) can augment mesoderm induction ([@bib55]), leading to cardiomyogenesis in ESCs ([@bib32]). Recombinant proteins BMP4 and ACTIVIN-A (INHBA) have similarly been used to induce mesoderm and cardiac muscle from ESCs ([@bib29; @bib39]). These studies implicate BMP4/INHBA or CHIR treatment as a potential method for generating skeletal muscle. Furthermore, we have shown that overexpression of WNT3A or CTNNB1 enhances the formation of premyogenic mesoderm in P19 embryonal carcinoma cells, resulting in increased myogenesis ([@bib42]). The loss of CTNNB1 function via dominant-negative mutation or knockdown results in the loss of MPC formation and myogenesis, supporting the use of CHIR to induce myogenesis.

The PAX3/7 population that is present in the central dermomyotome appears to represent an MPC pool that is maintained throughout embryogenesis and is responsible for almost all skeletal muscle ([@bib9; @bib31]). FGF2 prevents expression of the myoblast commitment transcription factors MYF5, MYOD1, and MYOG---collectively known as the myogenic regulatory factors (MRF)---during satellite cell activation and thus can be utilized to enhance proliferation of PAX3/7 expressing MPCs in vitro ([@bib23; @bib26]). Satellite cells are more efficient in reconstituting the satellite cell niche during transplantation into muscle if they do not yet upregulate the MRFs ([@bib31; @bib38]). We have previously shown that N2 supplemented media can enhance the terminal differentiation of myoblasts and myocytes, which would ensure MPCs are capable of complete myogenesis in vitro ([@bib2; @bib50]).

In this report, we describe the robust skeletal myogenesis of hESCs and mESCs using CHIR to induce mesoderm, FGF2 treatment to expand the MPC population, and N2-mediated terminal differentiation. This chemically defined, serum- and transgenic-free protocol yields a nearly homogeneous myogenic population from hESCs, consisting of 43% ± 4% PAX7^+ve^ MPCs and 47% ± 3% Myosin Heavy Chain^+ve^ (MYH) skeletal muscle.

Results {#sec2}
=======

GSK3 Inhibition Enhanced Premyogenic Mesoderm Formation from Human ESC {#sec2.1}
----------------------------------------------------------------------

Our objective was to devise a robust, serum-free directed differentiation method to obtain skeletal muscle from hESC in vitro. We adapted a recently developed chemically defined, feeder-free culture system to both expand pluripotent cells and induce mesoderm differentiation ([@bib13]). E8 maintenance media and Matrigel extracellular matrix were observed to support pluripotency based on OCT4 expression, and hESCs retained a normal karyotype after prolonged collagenase passaging (data not shown). Removal of FGF2 and TGFB1 from E8 media---referred to as E6 media---was observed to support cell expansion, but not pluripotency based on the loss of OCT4, SOX2, and NANOG gene and protein expression. Therefore, E6 medium provided a basal medium to which myogenic-inductive signaling molecules could be added. To control seeding density during differentiation procedures, hESCs were seeded as single cells in E8 media supplemented with ROCK inhibitor (Y27632) ([@bib24]). After overnight seeding, E8 media and ROCK inhibitor were removed and replaced with mesendoderm inductive conditions (R.L.C., S-P.D., and W.L.S., unpublished data).

Because previous studies have shown that CHIR or BMP4/INHBA treatment enhanced mesoderm induction in hESCs ([@bib10; @bib29; @bib32]), we initially sought to determine an optimal dose of CHIR and/or BMP4/INHBA to induce premyogenic mesoderm. For optimization of CHIR treatment, concentrations of 2.5 and 10 μM were chosen to encompass a range of concentrations previously used to induce cardiac tissue-fated mesoderm ([@bib10; @bib32]). Cells were plated on matrigel-coated dishes overnight in the presence of Y-27632 before differentiation was induced ([@bib24]). Factors maintaining pluripotency were removed from the media and treated with CHIR or vehicle for 2, 4, and 8 days in length: time points that encompass expression of *T* and early somite markers *PAX3* and *MEOX1* in serum-EB induced skeletal myogenesis ([@bib50]). Analysis by quantitative PCR (qPCR) showed significant upregulation of *T* and *MSGN1* after 2 days of treatment with 10 μM CHIR, leading to significant upregulation of *PAX3* on day 8 ([Figure 1](#fig1){ref-type="fig"}A). Although 2.5 μM CHIR treatment was able to upregulate *T* and *MSGN1* expression after 2 days of treatment, it did not upregulate *PAX3* at day 8 for any treatment length. Longer application of 10 μM CHIR, for 4 or 8 days, did not enhance *PAX3* expression as effectively and appeared to have toxicity toward the cells (data not shown). *MEOX1* gene expression appeared similar between both CHIR concentrations. Thus, the application of 10 μM CHIR for the first 2 days of differentiation was determined optimal for enhancing the formation of PAX3^+ve^ premyogenic mesoderm.

We titrated levels of BMP4/INHBA to optimize *T* expression and found by qPCR that 40 ng/ml of BMP4/INHBA enhanced *T* transcript levels, although not as efficiently as CHIR treatment ([Figure 1](#fig1){ref-type="fig"}B). Furthermore, BMP4/INHBA treatment did not significantly enhance *MSGN1* expression, suggesting a lack of skeletal muscle-fated mesoderm. Thus, CHIR treatment was better than BMP4/INHBA treatment to induce premyogenic mesoderm in hESCs.

CHIR Treatment Resulted in up to 90% of hESCs Entering the Myogenic Lineage {#sec2.2}
---------------------------------------------------------------------------

hESCs were differentiated using the 2 day CHIR treatment protocol devised in [Figure 1](#fig1){ref-type="fig"}A and cultured until day 50 as summarized in [Figure 1](#fig1){ref-type="fig"}C, outlining the stages of myogenesis and the chief chemical and recombinant factor additions. Live-cell imaging was performed, showing the progressive morphological changes from stem cells to myotubes ([Figure 1](#fig1){ref-type="fig"}D). CHIR-treated cells appeared morphologically distinct from control cells by day 2 of differentiation, and proliferation was reduced as judged by lower confluency compared to controls.

By day 8, CHIR-treated cells developed distinct 3D cell clusters ([Figure 1](#fig1){ref-type="fig"}D, white arrowheads) ([@bib48]). FGF2 was applied from days 12 to 20, which corresponds to the time frame that we previously detected somite or MPC markers *PAX3*, *MEOX1*, and *PAX7* along with *MYF5* ([@bib50]). Therefore, this time frame was an ideal target for FGF2 treatment to preferentially expand MPCs while suppressing early potential expression of the MRFs. N2 supplemented media was applied at day 35---coinciding with later detection of all MRFs previously ([@bib50])---to promote maturation of the myogenic cultures. Skeletal myocytes were observed by day 40, following 5 days of culture in N2 medium ([Figure 1](#fig1){ref-type="fig"}D, black arrowheads). The myocytes were, for the most part, randomly arranged among other nonbipolar cells. By day 50, cultures revealed large areas of aligned myocytes and fused myotubes, organized radially outward from the 3D clusters ([Figure S1](#app2){ref-type="sec"} available online). No appreciable skeletal myogenesis was observed in control cultures that were given DMSO vehicle in place of CHIR from days 0 to 2 and treated identically to CHIR-treated cells thereafter. Thus, CHIR treatment resulted in the formation of abundant mesoderm that could be developed into easily visualized myocytes and myotubes by day 50 of differentiation.

CHIR treatment resulted in detection of T protein in an average of 91% ± 6% of cells on day 2, compared to no T present in the control-treated cells ([Figures 2](#fig2){ref-type="fig"}A and 2E). At day 8, an average of 58% ± 10% of cells expressed PAX3 after CHIR treatment compared to 1% ± 1% in control cells ([Figures 2](#fig2){ref-type="fig"}B and 2F). Skeletal myocytes were prominent by day 40 following 5 days of growth in N2 medium, with an average of 14% ± 3% of CHIR-treated hESCs expressing MYH and were surrounded by a 37% ± 2% population of PAX7^+ve^ cells ([Figures 2](#fig2){ref-type="fig"}C and 2G). In addition to myocytes, some myotubes were present ([Figure S2](#app2){ref-type="sec"}A, white arrowheads), and skeletal muscle contractions could be observed by light microscopy ([Movie S1](#mmc2){ref-type="supplementary-material"}). When the cultures were left in N2 media from day 35 until day 50, 43% ± 4% of cells remained PAX7 positive, whereas 47% ± 3% were MYH positive ([Figures 2](#fig2){ref-type="fig"}D and 2G). A macroscopic view of the culture dishes suggests that the 3D clusters function as myogenic foci, with high concentrations of PAX7^+ve^ cells delaminating from their edges and myocytes/myotubes emanating outward ([Figures S2](#app2){ref-type="sec"}B and S2C). Thus, CHIR/FGF2/N2 treatment can induce around 90% of hESCs to enter the myogenic lineage.

We also quantified total cell number at various time points to investigate the scalability of hESC-derived myogenic cells with our protocol. The total cell number followed a logarithmic growth curve over the course of the differentiation protocol, resulting in roughly 20-fold more cells at day 50 compared to the initial number present at day 0 ([Figure 2](#fig2){ref-type="fig"}H). We also characterized the proliferation potential of our MPCs at day 50 by ethynyl-deoxyuridine (EdU) incorporation ([Figures 2](#fig2){ref-type="fig"}I and [S2](#app2){ref-type="sec"}D). During a 4 hr labeling pulse, 42% ±10% of PAX7^+ve^ MPCs incorporated EdU, demonstrating that our differentiation protocol yields a persistent population of actively proliferating MPCs at the final time point assayed in these studies.

We examined the temporal pattern of expression of myogenic factors by qPCR during CHIR-directed differentiation of hESCs to confirm the immunofluorescence results. Day 2 of CHIR-treated hESCs showed significant upregulation of *T* transcripts, that was orders of magnitude higher than our previous results using a serum/EB method ([Figure 3](#fig3){ref-type="fig"}A) ([@bib50]). Significant upregulation of the paraxial mesoderm markers *MSGN1* and *TBX6* accompanied *T* at day 2, and all were downregulated by day 8, which marked peaks of the premyogenic mesoderm genes *PAX3* and *MEOX1* ([Figure 3](#fig3){ref-type="fig"}B), in agreement with our previously published results ([@bib50]). Two control patient-derived iPSC lines showed similar mesoderm gene elevation in response to our CHIR-based protocol (data not shown).

Expression of *PAX3* and *MEOX1* was downregulated by day 25, although significant levels were still detected until day 50 (data not shown). Although *PAX7*, *MYF5*, *MYOD1*, and *MYOG* transcripts were significantly upregulated by day 25, their expression continued to increase until day 50 ([Figure 3](#fig3){ref-type="fig"}C). Expression of *MYH3* transcripts also increased at days 40 and 50, suggesting an enduring MPC population coexisting with terminally differentiated skeletal myocytes/myotubes in agreement with our immunofluorescence data ([Figures 2](#fig2){ref-type="fig"}D, 2G, 2I, and [S2](#app2){ref-type="sec"}D). Control cells showed no significant expression of *MYF5*, *MYOD1*, or *MYH3* transcripts. There was, however, very low but statistically significant upregulated expression of *PAX7* and *MYOG* mRNA in control cells. Overall, CHIR-treated cells exhibited waves of expression of mesoderm, presomitic mesoderm, muscle progenitor, myoblast, and muscle structural genes.

Because Wnt signaling is important for the development of a multitude of tissues and not simply premyogenic mesoderm ([@bib15]), we screened our cultures for markers of other lineages. Therefore, we assayed for other cell types that may be present in the 9% T^−ve^ cells early in differentiation, and later in the 10% of PAX7^−ve^/MYH^−ve^ cells. CHIR treatment led to a significant drop in the pluripotency marker *SOX2* ([Figure 4](#fig4){ref-type="fig"}A) by day 2, indicating an efficient loss of pluripotency. *SOX2* is also expressed in ectoderm lineages pertaining to the neural tube and future spinal cord ([@bib16; @bib63]). Thus, levels of these tissues in our day 8 CHIR cultures should be low for *SOX2* expression. *FOXA2*---a marker of notochord, floor plate, and future endoderm ([@bib37; @bib52])---was reduced in both CHIR-treated and control cells. Significant upregulation of *NOG* and *SOX10* was detected at day 8 of CHIR-mediated differentiation, which conventionally mark the roof plate and neural crest during embryonic development ([@bib45; @bib59]). Although neural crest cells may have been present early in differentiation, there was no significant upregulation in the neuronal marker *NEUROG1* at later time points ([Figure 4](#fig4){ref-type="fig"}B), and immunofluorescent staining for NEFL---a neurofilament protein expressed in central and peripheral nervous system axons---was also negative (data not shown). Significant expression of traditional cardiac muscle lineage genes *NKX2-5* and *MYH6* ([@bib1; @bib36]) was detected with CHIR treatment at day 50, although cells exhibiting a cardiac muscle phenotype were not readily observed in these cultures ([Figure S2](#app2){ref-type="sec"}B). As *NKX2-5* and *MYH6* have previously been detected in developing tongue skeletal muscle ([@bib22]), we also assessed additional markers that are expressed exclusively in cardiomyocytes, *NPPA* and *MYL2*. No expression of these markers was detected in our day 50 differentiated cultures ([Figure 4](#fig4){ref-type="fig"}C). Therefore, neither mature neuronal tissue nor cardiac muscle were present in terminally differentiated cultures.

To determine the patterning of the dermomyotome, we performed qPCR for the regional dermomyotome markers *EN1*, *SIM1*, *LBX1*, and *MET* ([Figure 4](#fig4){ref-type="fig"}D). The dermomyotome is patterned into the dorsomedial half---expressing *EN1* and giving rise to epaxial muscle, forming the deep back muscles---and the ventrolateral half, expressing *SIM1* and giving rise to hypaxial muscle, forming the ventral and limb muscle ([@bib14; @bib41; @bib44]). Proper migration of the hypaxial MPCs into the limb requires the expression of *LBX1* and *MET* ([@bib60]). Therefore, presence of *LBX1* and *MET* expression would support the existence of MPCs similar to those found in migrating limb muscle. We found a significant increase of the three regional markers of the dermomyotome---*EN1, SIM1*, *LBX1*---and a trend toward elevated *MET* with CHIR. However, *MET* was expressed at high levels throughout the differentiation, shown by low Ct values, making changes as a result of CHIR-treatment difficult to identify (data not shown). Thus, day 25--50 cultures containing muscle progenitors expressed markers of epaxial, hypaxial, and migratory dermomyotome.

CHIR Treatment Enhanced Skeletal Myogenesis in Mouse ESCs {#sec2.3}
---------------------------------------------------------

A similar CHIR-based differentiation protocol was performed in mouse embryonic stem cells (mESCs) and compared with BMP4/INHBA-mediated differentiation. Pax3/7^+ve^ cells, presumably representing MPCs, were present in both BMP4/INHBA- and CHIR-treated mESCs at day 15, although PAX3/7^+ve^ cells were visibly more abundant with CHIR ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, MYH staining primarily revealed cardiomyocytes in BMP4/INHBA-treated cultures despite the presence of PAX3/7^+ve^ cells ([Figure 5](#fig5){ref-type="fig"}B). CHIR, conversely, promoted the differentiation of primarily skeletal and not cardiac myocytes. Control cultures showed negligible or no staining with either PAX3/7 or MYH antibodies. Thus, CHIR treatment upregulated PAX3/7 expression, leading to enhanced skeletal myogenesis in mESCs.

Established markers of skeletal myogenesis were examined by qPCR and demonstrated corroborating trends between CHIR-induced differentiation in mESCs and hESCs ([Figure 5](#fig5){ref-type="fig"}C). Indeed, CHIR treatment significantly enhanced the expression of key paraxial mesoderm, premyogenic mesoderm, and MRF genes, including *T*, *Msgn1*, *Pax3*, *Meox1*, *Myod1*, *Myog*, and *Myh3*. BMP4/INHBA-treated cells exhibited some upregulation of the same mesodermal genes. However, BMP4/INHBA treatment did not upregulate expression of the MRFs but did upregulate high levels of the cardiomyocyte markers *Nkx2-5* and *Myh6*. Thus, mESCs respond to CHIR treatment by upregulating a similar set of muscle lineage genes as identified in hESCs, albeit in a much-reduced time frame.

Discussion {#sec3}
==========

Our studies define a method whereby human and mouse ESCs are differentiated in vitro into highly enriched populations of skeletal muscle progenitor cells and myocytes/myotubes by activating Wnt signaling via the GSK3 inhibitor CHIR99021. A mere 2 day exposure to the compound causes immediate changes in growth and morphology toward mesoderm, and sets in motion downstream cascades of myogenic transcription factors across weeks of culture. In due course, we achieve approximately 90% purity of skeletal muscle lineage cells from hESCs after 50 days in culture.

Although forced expression of PAX3/7 or MYOD in hESCs have resulted in enriched myogenic populations ([@bib3; @bib20; @bib25; @bib46]), we sought to develop a viral- and transgenic- free method of in vitro differentiation. A chemically defined protocol should be more readily adaptable to a broader number of cell lines and should allow for the examination of all of the stages of differentiation, some of which may be bypassed by transgenic overexpression ([@bib3]).

Our study contrasts with previously published methods of transgene-free hESC myogenesis that were dependent upon serum, showing low overall myogenic induction and/or myogenic progenitor formation ([@bib6; @bib28; @bib50]). For example, we previously obtained a 4% level of MYH^+ve^ skeletal myocytes and 7% PAX3^+ve^ MPCs with RA treatment ([@bib50]). Our current CHIR-directed protocol improves on the serum/EB methods by directing a larger proportion of the cultures into mesoderm, leading to enriched myogenic lineage populations.

Several studies have shown that Wnt signaling modulation by CHIR can maintain ESC pluripotency ([@bib64]), and also can cause differentiation into tissues of all three germ layers ([@bib21; @bib32; @bib53]). However, supporting factors were required immediately following CHIR treatment for these approaches. Cell seeding density may also determine how GSK3 inhibition can generate skeletal muscle specific mesoderm versus other cell fates. Seeding density was critical first and foremost in determining how hESCs responded to external differentiation cues in our system (R.L.C., S-P.D., and W.L.S., unpublished data). At lower seeding densities (\<1 × 10^5^ cells/ml), hESC survival was reduced even in the presence of ROCK inhibitor, suggesting that cell-cell contacts are important for the initial seeding process. Additionally, sparse populations of cells responded to BMP4/INHBA treatment with increased cell death compared to higher densities. Furthermore, at higher seeding densities (\>2 × 10^5^ cells/ml), overconfluence was observed after 48 hr, again leading to compromised cell viability. Other monolayer approaches have used GSK3 to drive cardiomyogenesis; however, these protocols induce GSK3 inhibition once cells reach confluence or with supplemental BMP4 inhibition ([@bib10; @bib32]). These protocols also emphasize the critical importance of insulin depletion after GSK3 inhibition, or the need for Wnt inhibition following mesoderm induction lest cardiomyogenesis will not occur in vitro ([@bib29; @bib33]). This is supported by the role of Dkk-mediated Wnt inhibition in specifying embryonic mesoderm to the primary heart field ([@bib58]).

Of particular relevance to the results presented in our study was the differentiation of mesoderm from hESCs via 5 days of 5 μM CHIR treatment ([@bib55]). Intermediate to the desired cell types, CHIR treatment caused a marked upregulation of T mRNA and protein levels, similar to our findings. Though the authors followed CHIR treatment with BMP4---which typically effects lateral plate mesoderm---to develop hematopoietic and endothelial cell types and not skeletal muscle ([@bib43; @bib49]). They also found INHBA following CHIR treatment was necessary for pronounced endoderm commitment ([@bib55]).

Although CHIR can coax differentiation of hESCs into all three germ layers, we obtained surprisingly 43% ± 4% PAX7^+ve^ and 47% ± 3% MYH^+ve^ cell populations at the experimental endpoint. However, trace expression of other ectoderm and mesoderm lineages can be detected early in the protocol. It is possible that other tissues, such as neural crest present early in our protocol, aid in the myogenic differentiation pathway; attempts to reach 100% T^+ve^ cultures could demand additional signaling molecules to replace factors from these tissues ([@bib40; @bib47]). It is likely that our current protocol can still be improved by the inclusion of additional signaling molecules at the correct time in the pathway, such as RA and Notch signaling, and/or by the use of fluorescence-activated cell sorting (FACS) or microdissection to further enrich the MPCs.

Indeed, we attempted to improve our protocol according to a recent study published while our manuscript was in review that generated high proportions of skeletal myocytes from aggregated human iPSCs using combinatorial treatment with CHIR, FGF2, and the cAMP signaling activator Forskolin ([@bib65]). Hence, we included Forskolin in our culture system to determine whether activation of cAMP signaling with could improve skeletal myocyte yield in the context of our protocol ([Figure S3](#app2){ref-type="sec"}). qPCR analysis showed that, in the context of our monolayer differentiation protocol with 10 μM CHIR alone, Forskolin does not provide additional benefit to myogenesis as it does with aggregate based differentiation. By day 7, however, conditions that included Forskolin were observably denser than CHIR alone treated cultures, suggesting that Forskolin increases cell proliferation (data not shown). One major difference between our protocol and the published work by Zon and colleagues is that the myogenic cultures generated with Forskolin treatment appear to terminally differentiate beyond the MPC stage to over 90% MYOG^+ve^ ([@bib65]), whereas our system maintained a significant population of proliferating PAX7^+ve^ MPCs ([Figures 2](#fig2){ref-type="fig"}D, 2G, 2I, and [S2](#app2){ref-type="sec"}D), suggesting that our culture system will provide replicative MPCs that could maintain homeostasis in the transplanted muscle.

During the revisions of this manuscript, two additional manuscripts were published that generated transgene-free human ESC myocytes. Barberi and colleagues utilized a lower concentration of CHIR and longer treatment duration to direct skeletal myogenesis in embryonic stem cells ([@bib8]). We initially determined that similar CHIR conditions used by [@bib8] induced less skeletal muscle-specific mesoderm than the optimal 10 μM for 2 days ([Figure 1](#fig1){ref-type="fig"}A). Indeed, our protocol generated twice as many PAX7^+ve^ MPCs at comparable time points ([Figures 2](#fig2){ref-type="fig"}C and 2G). This recent publication, however, introduced a rigorous HNK^−^/ACHR^−^/CXCR4^+^/MET^+^ FACS profile for isolating MPCs from bulk cultures. Therefore, future studies in embryonic-derived MPCs may benefit from implementing our differentiation protocol to generate greater numbers of starting cells, which could be enriched via the HNK^−^/ACHR^−^/CXCR4^+^/MET^+^ profile.

In addition, Suzuki and colleagues present a viable alternative to monolayer directed skeletal myogenesis ([@bib27]). The authors' "EZ Sphere" suspension-culture system uses high concentrations of FGF2 and EFGF to yield remarkably similar proportions of PAX7^+ve^ populations at the experimental endpoint as those presented here ([Figures 2](#fig2){ref-type="fig"}D, 2G, 2I, and [S2](#app2){ref-type="sec"}D). One caveat to the EZ Sphere method, however, is potentially upward of 30% of cells are neural progenitors ([@bib27]).

We show that CHIR can mediate efficient skeletal myogenesis in mESCs using a 2 day CHIR treatment similar to that used for hESCs, illustrating the effectiveness of our protocol across these species. Our current findings are consistent with our previous results showing that Wnt signaling via CTNNB1 is important for murine P19 embryonal carcinoma cell differentiation, using gain- and loss-of-function as well as a dominant-negative approach ([@bib42; @bib62]). In addition, the greater experimental variability with mouse compared to human ESC differentiation into muscle could be due to the EB-based nature of the mESC serum-free protocol. Therefore, we are adapting the more consistent monolayer approach used with our hESC method to mESCs. Although hESCs are more therapeutically relevant, mESCs continue to play an integral role in our ability to study cellular differentiation, primarily due to their substantially shorter differentiation time, creating a simpler high-throughput model system for detailed molecular analysis.

Overall, the results presented here have provided a method to differentiate mouse and human ESCs into highly enriched skeletal muscle lineage cultures. Most importantly, we show a stable PAX7^+ve^ population of MPCs even after 7 weeks of culture. Ultimately, these studies provide the foundation for in vitro study of ESC skeletal myogenesis, which could contribute to future drug testing or stem cell therapies, leading to the repair of muscle in patients with muscular wasting disorders.

Experimental Procedures {#sec4}
=======================

Human Cell Culture {#sec4.1}
------------------

All hESC media and components are formulated in [Table S1](#app2){ref-type="sec"}. H9 hESCs were maintained feeder free on BD Matrigel (BD Bioscience) -coated dishes in E8 media prepared in lab ([@bib12; @bib13; @bib57]).

Cells were prepared for differentiation by plating 1.5 × 10^5^ cells per well on BD Matrigel coated 12-well dishes in E8 supplemented with 10 μM Y-27632 (Tocris Bioscience) overnight. The medium was then replaced with E6 medium ([@bib57]), supplemented with CHIR99021 (Tocris Bioscience) or BMP4 and INHBA (R&D Systems) for 2 days. DMSO was used as the vehicle control at a final concentration of 0.1%. CHIR99021 or BMP4 and INHBA were washed out at day 2, and cells were grown in unsupplemented E6 until day 12. From days 12 to 20, the medium was replaced with StemPro-34 media. Cells were returned to E6 media from days 20 to 35. The medium was then replaced with N2 medium until the endpoint of the experiment. All media were changed daily. When indicated ([Figure S3](#app2){ref-type="sec"}), 20 μM Forskolin (Tocris Bioscience) and 10 ng/ml FGF2 was used from days 0 to 7 in conjunction with 0.5 μM CHIR99021, or from days 2 to 7 following 2 days of 10 μM CHIR99021 treatment.

Mouse Cell Culture {#sec4.2}
------------------

All mESC media and components are formulated in [Table S2](#app2){ref-type="sec"}. R1 mESCs were maintained feeder free and passaged every other day in Maintenance Media, prepared in lab.

Cells were prepared for differentiation by plating 5 × 10^5^ cells on 0.1% gelatin coated 10 cm dishes overnight in Serum Free Maintenance Media to deplete serum ([@bib29]). The cells were then trypsinized and aggregated into embryoid bodies at 1 × 10^5^ cells/ml on Petri dishes in Serum Free Differentiation Medium for 2 days. At day 2, EBs were trypsinized and reaggregated at 1 × 10^5^ cells/ml on Petri dishes in Serum Free Differentiation Media---supplemented with 5 ng/ml VEGF (R&D Systems), and either CHIR99021 or BMP4/INHBA---from days 2 to 4 of differentiation. DMSO was used as the vehicle control at a final concentration of 0.1%. From days 4 to 10, the medium was replaced with StemPro-34 Media. EBs were plated on BD Matrigel coated dishes on day 6. The medium was replaced at day 10 with N2 medium until the endpoint of the experiment. All media were changed every other day.

Gene Expression Analysis {#sec4.3}
------------------------

RNA was isolated from cells using either the RNeasy kit (QIAGEN) or Total RNA Mini Kit (FroggaBio). RNA ranging from 0.2 to 1 μg of each sample was reverse transcribed using the Quantitect Reverse Transcription kit (QIAGEN). qPCR was carried out using a Mastercycler Realplex and analyzed with Realplex software (Eppendorf). For real-time detection of mRNA expression, 1/40 of the total first strand synthesis product was used as a template for PCR amplification using either GoTaq qPCR Master Mix (Promega) or Kapa SYBR Fast qPCR kit (Kapa Biosystems). Primer pairs ([Table S3](#app2){ref-type="sec"}) were selected from PrimerBank ([@bib61]) or generated by Primer-BLAST ([@bib4]) and tested for equivalent efficiency. Each reaction was carried out in duplicate, and fold changes were calculated using the comparative Ct method as described earlier ([@bib35]). The resulting Ct values were normalized to either *GAPDH* in hESCs or *Actb* in mESCs. Results are shown ±SE of the mean of three independent experiments, unless otherwise stated.

Immunofluorescence {#sec4.4}
------------------

Cells were fixed for immunofluorescence with 4% formaldehyde for 15 min and permeabilized with PBS containing 0.5% Triton X-100 for 10 min. Cells were then blocked for 1 hr with PBS containing 0.1% bovine serum albumin, 0.1% Triton X-100, and 10% goat or donkey serum. Primary antibodies against T (Abcam), PAX3 (R&D Systems), PAX7 and MF20 (Developmental Studies Hybridoma Bank), or NEFL (Sigma-Aldrich) were incubated overnight at 4°C. Cy3-conjugated donkey anti-rabbit, goat anti-mouse IgG2a, goat anti-mouse IgG2b, Alexa-488-conjugated donkey anti-goat, and DyLight488-conjugated goat anti-mouse IgG1 secondary antibodies (Jackson ImmunoResearch) were used for detection as appropriate for 1 hr at room temperature. Cells were mounted in sPBS:glycerol containing Hoechst dye to identify cell nuclei. EdU labeling was performed using the Click-iT EdU Alexa Fluor488 Imaging Kit (Life Technologies). Cells we pulsed with EdU for 4 hr before fixing and staining as per the manufacturer's protocol.

Cells were visualized with a Leica DMI6000 B microscope (Leica Microsystems), and pictures were acquired using a Micropublisher 3.3 RTV camera (Q Imaging). Staining was quantified by performing either manual or automated cell counts using the Volocity software (PerkinElmer) and represented as a proportion of total nuclei. On average, 2.5 × 10^4^ cells were quantified from each experiment. Results are shown ±SE of the mean of three independent experiments.

Statistical Analysis {#sec4.5}
--------------------

Statistical differences between means were calculated using the Student's t test. p values ≤ 0.05 were considered significant.

Supplemental Information {#app2}
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![Ten Micromolar CHIR Applied for 2 Days Produces Optimal Levels of Paraxial and Premyogenic Mesoderm Gene Expression\
(A) hESCs were treated in monolayer with or without 2.5 or 10 μM CHIR for 2, 4, or 8 days. RNA was harvested at days 0, 2, and 8 to be analyzed by qPCR for markers of early and premyogenic mesoderm. Results are expressed as fold change over day 0 (n = 3 independent experiments, ^∗^p ≤ 0.05 versus day 0, ^∗∗^p ≤ 0.05 versus day 0 and control, ^∗∗∗^p ≤ 0.05 2.5 versus 10 μM).\
(B) CHIR-differentiated cells were compared to BMP4/INHBA treatment by qPCR for markers of early mesoderm. (n = 3 independent experiments, ^∗^p ≤ 0.05 versus day 0, ^∗∗^p ≤ 0.05 versus day 0 and control, ^∗∗∗^p ≤ 0.05 BMP4/INHBA versus CHIR).\
(C) Schematic overview of the CHIR directed differentiation of hESCs on a nonlinear scale timeline, along with highlighting key supplemental factors applied during the differentiation, and the predicted developmental stages of skeletal myogenesis.\
(D) Representative phase contrast live-cell images demonstrating the progressive changes in hESC morphology with and without CHIR treatment. 3D cell clusters (white arrowheads) and the presence of skeletal myocytes (black arrowheads) are indicated at specific time points (scale bar, 20 μm).\
Results are shown ±SEM.](gr1){#fig1}

![CHIR Directed Differentiation of hESCs Induces up to a 90% Myogenic Population\
(A--G) hESCs were differentiated as described in [Figure 1](#fig1){ref-type="fig"}. Myogenic induction was quantified by staining with antibodies against (A) and (E) T at day 2, (B) and (F) PAX3 at day 8, (C) and (G) MYH and PAX7 at day 40, and (D) and (G) MYH and PAX7 at day 50. Target populations are expressed as a percentage of total number of cells, which was quantified by Hoechst staining (n = 3 independent experiments, ^∗^p ≤ 0.05 versus control, ^∗∗^p ≤ 0.05 day 40 versus day 50, scale bar, 20 μm).\
(H) Total number of cells was obtained by trypsinizing and counting one well of a 12-well culture dish at various time points of the differentiation protocol (n = 3 independent experiments).\
(I) Day 50 CHIR-treated cells were pulsed with EdU for 4 hr and fixed and stained additionally with PAX7. EdU and PAX7 single or double-positive cells were quantified and expressed as percentage of total number of cells (n = 3 independent experiments).\
Results are shown ±SEM.](gr2){#fig2}

![qPCR Profiling of CHIR-Treated hESCs Highlights a Clear Progression through Specified Mesodermal Subtypes, Muscle Progenitor Stages, and Committed Myogenic Cultures\
hESCs were differentiated as described in [Figure 1](#fig1){ref-type="fig"}. RNA was harvested at days 0, 2, 8, 25, 40, and 50 to be analyzed by qPCR for markers several of (A) early and paraxial mesoderm, (B) premyogenic mesoderm, and (C) committed or differentiated skeletal muscle. Results are expressed as fold change over day 0 (n = 3 independent experiments, ^∗^p ≤ 0.05 versus day 0, ^∗∗^p ≤ 0.05 versus control).\
Results are shown ±SEM.](gr3){#fig3}

![Low Levels of Neural Crest Transcripts Were Present in CHIR-Treated Cultures\
hESCs were differentiated, harvested, and analyzed as described above for markers of (A) pluripotency and neural ectoderm markers, (B) differentiated neural and traditional cardiac markers, (C) specific markers of mature cardiomyocytes, and (D) patterned dermomyotome genes (n = 3 independent experiments, ^∗^p ≤ 0.05 versus day 0, ^∗∗^p ≤ 0.05 versus control). In (C) RNA from serum-differentiated hESCs and human heart (HH) cardiomyocyte-positive controls were obtained (n = 1). All hESC fold changes (black bars) were plotted on the primary y axis, and HH fold change (gray bar) was plotted on the secondary y axis.\
Results are shown ±SEM.](gr4){#fig4}

![CHIR Enhances Skeletal Myogenesis in a 15 Day Differentiation of mESCs\
mESCs were aggregated in differentiation medium for 2 days prior to treatment. CHIR, BMP4/INHBA, or vehicle control was applied from days 2 to 4.\
(A and B) Immunofluorescent staining was carried out at day 15 with antibodies against (A) PAX3 and PAX7 or (B) MYH (scale bar, 20 μm).\
(C) RNA was harvested at days 0 and 2 (prior to CHIR treatment) and days 4, 6, and 15 (following treatment). Samples were analyzed by qPCR for select markers of skeletal and cardiomyogenesis.\
Results are expressed relative to the maximum fold change over day 0 (n = 3 independent experiments, ^∗^p ≤ 0.05 versus day 0, ^∗∗^p ≤ 0.05 versus day 0 and control, ^∗∗∗^p ≤ 0.05 BMP4/INHBA versus CHIR). Results are shown ±SEM.](gr5){#fig5}
